The Phase 2 ASSERT clinical trial's lead compound RVX-208 is an orally
active small molecule that raises Apolipoprotein A-I (ApoA-I)
production, the key protein in high-density lipoprotein (HDL) known as
the 'good cholesterol'. Data gathered in the ASSERT trial showed that
RVX-208 enhanced biomarkers of reverse cholesterol transport (RCT),
thus reflecting robust cholesterol clearance from arterial wall plaques
via this metabolic pathway. This action of RVX-208 is unique and when
added to new knowledge of the target protein bound by the compound, it
indicates that RVX-208 is clearly different from all other drugs in the
sphere, including cholesteryl ester transfer protein (CETP) inhibitors.

The current analysis of the ASSERT trial yielded new findings summarized
in the presentation titled: "Increasing Circulating Concentration of
all HDL Particle Subclasses in Hyper-Responders: Insights from the
ASSERT Study to ApoA-I Induction." Abstract link: http://spo.escardio.org/AbstractDetails.aspx?id=100468&eevtid=48

Dr. Jan Johansson, Resverlogix's Senior Vice President of Medical
Affairs, highlighted the significance of this observation noting that,
"enhanced RCT is a highly sought after goal in drug development because
it gives us a chance to regress atherosclerosis within the vessel
wall. This new data helped identify a large high-risk patient
population with low HDL levels whereby significant benefit may be
gained from the actions of RVX-208."

The second ESC presentation titled: "Apolipoprotein A-I Induction
Therapy is Associated with Reduction in Inflammatory Biomarkers:
Potential Implications for Functionality of High-Density Lipoproteins,"
demonstrated the potential of RVX-208 in lowering CRP, a recognized
biomarker of cardiovascular risk and inflammation. Abstract link: http://spo.escardio.org/AbstractDetails.aspx?id=97764&eevtid=48

"These new observations are valuable in advancing our Phase 2b ASSURE
clinical trial of RVX-208 to examine atherosclerosis regression using
intravascular ultrasound (IVUS) and biomarkers of RCT for 26 weeks in
patients with Coronary Artery Disease," said Donald J. McCaffrey,
President & Chief Executive Officer of Resverlogix. "This new data in
the two ESC presentations has not only enriched our understanding of
how RVX-208 can augment RCT, and thus enable regression of
atherosclerosis, but also the expanded therapeutic potential of RVX-208
in alternate indications."

About RVX-208

RVX-208 is a novel small molecule therapeutic that facilitates
endogenous ApoA-I production. It is positioned to be one of the most
promising emerging drugs in development for the treatment of
atherosclerosis. To the Company's knowledge, RVX-208 is the only novel
small molecule that is specifically designed to increase ApoA-I
production and thereby raise HDL levels thus enhancing HDL
functionality to augment RCT and ultimately plaque regression. RCT is a
pathway by which cholesterol that has accumulated within the arterial
wall can be transported to the liver for excretion, thus reducing or
preventing atherosclerosis.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the
development of novel therapies for important global medical markets
with significant unmet medical needs. The NexVas™ Plaque Regression
program is the Company's primary focus which is to develop novel small
molecules that enhance ApoA-I production. These vital therapies are
focused to address the burden of atherosclerosis and other important
diseases such as Acute Coronary Syndrome, Alzheimer's disease,
Peripheral Artery Disease, and Autoimmune diseases. Resverlogix Corp.'s
common shares trade on the Toronto Stock Exchange (TSX:RVX). For
further information please visit www.resverlogix.com.

This news release may contain certain forward-looking information as
defined under applicable Canadian securities legislation, including our
statements with respect to research, development and commercialization
of novel therapeutics that reduce the risk of cardiovascular and
autoimmune diseases including atherosclerosis, diabetes, Alzheimer's
disease, Peripheral Artery Disease and other vascular disorders that
are not based on historical fact, including without limitation
statements containing the words "believes", "anticipates", "plans",
"intends", "will", "should", "expects", "continue", "estimate",
"forecasts" and other similar expressions. Our actual results, events
or developments could be materially different from those expressed or
implied by these forward-looking statements. We can give no assurance
that any of the events or expectations will occur or be realized. By
their nature, forward-looking statements are subject to numerous known
and unknown risks and uncertainties including but not limited to those
risk factors discussed in the Company's Annual Information Form and
January 31, 2011 MD&A which are incorporated herein by reference and
other documents we file from time to time with securities authorities,
which are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are
expressly qualified by this cautionary statement and are made as of the
date hereof. The Company disclaims any intention and has no obligation
or responsibility, except as required by law, to update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise. The TSX Exchange does not accept
responsibility for the adequacy or accuracy of this news release.